A bloodâ based nutritional risk index explains cognitive enhancement and decline in the multidomain Alzheimer prevention trial

IntroductionMultinutrient approaches may produce more robust effects on brain health through interactive qualities. We hypothesized that a bloodâ based nutritional risk index (NRI) including three biomarkers of diet quality can explain cognitive trajectories in the multidomain Alzheimer prevention trial (MAPT) over 3â years.MethodsThe NRI included erythrocyte nâ 3 polyunsaturated fatty acids (nâ 3 PUFA 22:6nâ 3 and 20:5nâ 3), serum 25â hydroxyvitamin D, and plasma homocysteine. The NRI scores reflect the number of nutritional risk factors (0â 3). The primary outcome in MAPT was a cognitive composite Z score within each participant that was fit with linear mixedâ effects models.ResultsEighty percent had at lease one nutritional risk factor for cognitive decline (NRI â ¥1: 573 of 712). Participants presenting without nutritional risk factors (NRI=0) exhibited cognitive enhancement (β = 0.03 standard units [SU]/y), whereas each NRI point increase corresponded to an incremental acceleration in rates of cognitive decline (NRIâ 1: β = â 0.04 SU/y, P = .03; NRIâ 2: β = â 0.08 SU/y, P < .0001; and NRIâ 3: β = â 0.11 SU/y, P = .0008).DiscussionIdentifying and addressing these wellâ established nutritional risk factors may reduce ageâ related cognitive decline in older adults; an observation that warrants further study.Highlightsâ ¢Multiâ nutrient approaches may produce more robust effects through interactive propertiesâ ¢Nutritional risk index can objectively quantify nutritionâ related cognitive changesâ ¢Optimum nutritional status associated with cognitive enhancement over 3â yearsâ ¢Suboptimum nutritional status associated with cognitive decline over 3â yearsâ ¢Optimizing this nutritional risk index may promote cognitive health in older adultsPeer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/152935/1/trc2jtrci201911004.pd

Overexpression of Wild-Type Human Alpha-Synuclein Causes Metabolism Abnormalities in Thy1-aSYN Transgenic Mice

Parkinson’s disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons, pathological accumulation of alpha-synuclein and motor symptoms, but also by non-motor symptoms. Metabolic abnormalities including body weight loss have been reported in patients and could precede by several years the emergence of classical motor manifestations. However, our understanding of the pathophysiological mechanisms underlying body weight loss in PD is limited. The present study investigated the links between alpha-synuclein accumulation and energy metabolism in transgenic mice overexpressing Human wild-type (WT) alpha-synuclein under the Thy1 promoter (Thy1-aSYN mice). Results showed that Thy1-aSYN mice gained less body weight throughout life than WT mice, with significant difference observed from 3 months of age. Body composition analysis of 6-month-old transgenic animals showed that body mass loss was due to lower adiposity. Thy1-aSYN mice displayed lower food consumption, increased spontaneous activity, as well as a reduced energy expenditure compared to control mice. While no significant change in glucose or insulin responses were observed, Thy1-aSYN mice had significantly lower plasmatic levels of insulin and leptin than control animals. Moreover, the pathological accumulation of alpha-synuclein in the hypothalamus of 6-month-old Thy1-aSYN mice was associated with a down-regulation of the phosphorylated active form of the signal transducer and activator of transcription 3 (STAT3) and of Rictor (the mTORC2 signaling pathway), known to couple hormonal signals with the maintenance of metabolic and energy homeostasis. Collectively, our results suggest that (i) metabolic alterations are an important phenotype of alpha-synuclein overexpression in mice and that (ii) impaired STAT3 activation and mTORC2 levels in the hypothalamus may underlie the disruption of feeding regulation and energy metabolism in Thy1-aSYN mice

ACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic VAlve implantaTION): A Randomized Clinical Trial.

OBJECTIVES: This study sought to determine if percutaneous coronary intervention (PCI) prior to transcatheter aortic valve replacement (TAVR) in patients with significant coronary artery disease would produce noninferior clinical results when compared with no PCI (control arm). BACKGROUND: PCI in patients undergoing TAVR is not without risk, and there are no randomized data to inform clinical practice. METHODS: Patients with severe symptomatic aortic stenosis and significant coronary artery disease with Canadian Cardiovascular Society class ≤2 angina were randomly assigned to receive PCI or no PCI prior to TAVR. The primary endpoint was a composite of all-cause death or rehospitalization at 1 year. Noninferiority testing (prespecified margin of 7.5%) was performed in the intention-to-treat population. RESULTS: At 17 centers, 235 patients underwent randomization. At 1 year, the primary composite endpoint occurred in 48 (41.5%) of the PCI arm and 47 (44.0%) of the no-PCI arm. The requirement for noninferiority was not met (difference: -2.5%; 1-sided upper 95% confidence limit: 8.5%; 1-sided noninferiority test P = 0.067). On analysis of the as-treated population, the difference was -3.7% (1-sided upper 95% confidence limit: 7.5%; P = 0.050). Mortality was 16 (13.4%) in the PCI arm and 14 (12.1%) in the no-PCI arm. At 1 year, there was no evidence of a difference in the rates of stroke, myocardial infarction, or acute kidney injury, with higher rates of any bleed in the PCI arm (P = 0.021). CONCLUSIONS: Observed rates of death and rehospitalization at 1 year were similar between PCI and no PCI prior to TAVR; however, the noninferiority margin was not met, and PCI resulted in a higher incidence of bleeding. (Assessing the Effects of Stenting in Significant Coronary Artery Disease Prior to Transcatheter Aortic Valve Implantation; ISRCTN75836930)

Développement de sondes moléculaires appliquées à l’étude de la biosynthèse des flavonoïdes

Flavonoids are natural substances known for their anti-inflammatory, anti-cancerous and anti-virals properties in humans. In plants, they are one of the molecules responsible for fighting pathogens. The flavonoid biosynthesis pathway as been greatly studied in plants, especially in that of the grapevine: Vitis vinifera. However, detailed studies of the exact function of the enzymes involved in the last steps of the biosynthesis of anthocyanins and proanthocyanidins remains largely lacking.The study that we propose is to synthesize molecular probes designed to specifically interact with enzymes involved in the last stages of flavonoids biosynthesis. Our probes, based on the emerging chemical proteomic technology, activity- and affinity based protein profiling (ABPP), were validated with a model enzyme: leucoanthocyanidin dioxygenase (LDOX). After which, they were used with complex protein mixtures from Vitis vinifera.Les flavonoïdes sont des substances naturelles connues pour leurs propriétés anti-inflammatoires, anti-cancéreuses ou anti-virales chez l'homme. Chez les végétaux, ils participent notamment à leur protection vis-à-vis d'organismes pathogènes. La voie de biosynthèse des flavonoïdes est l'une des plus étudiées chez les plantes et notamment chez la vigne : Vitis vinifera. Cependant, la ou les enzymes impliquées dans les dernières étapes de biosynthèse conduisant aux anthocyanes et aux proanthocyanidines restent, à ce jour, peu ou pas connues. L’étude que nous proposons a pour but de concevoir des sondes moléculaires d’affinité susceptibles d’interagir avec une ou plusieurs enzymes impliquées dans ces dernières étapes de biosynthèse. Ces sondes, basées sur la technologie émergeante de protéomique chimique : « Activity- and affininity Based Protein Profiling » (ABPP), ont été validées à l’aide d’une enzyme modèle : la leucoanthocyanidine dioxygénase (LDOX). Elles ont ensuite été appliquées à des extraits complexes de protéines issus de Vitis vinifera

Molecular probes development for Flavonoid biosynthesis studying

Les flavonoïdes sont des substances naturelles connues pour leurs propriétés anti-inflammatoires, anti-cancéreuses ou anti-virales chez l'homme. Chez les végétaux, ils participent notamment à leur protection vis-à-vis d'organismes pathogènes. La voie de biosynthèse des flavonoïdes est l'une des plus étudiées chez les plantes et notamment chez la vigne : Vitis vinifera. Cependant, la ou les enzymes impliquées dans les dernières étapes de biosynthèse conduisant aux anthocyanes et aux proanthocyanidines restent, à ce jour, peu ou pas connues. L’étude que nous proposons a pour but de concevoir des sondes moléculaires d’affinité susceptibles d’interagir avec une ou plusieurs enzymes impliquées dans ces dernières étapes de biosynthèse. Ces sondes, basées sur la technologie émergeante de protéomique chimique : « Activity- and affininity Based Protein Profiling » (ABPP), ont été validées à l’aide d’une enzyme modèle : la leucoanthocyanidine dioxygénase (LDOX). Elles ont ensuite été appliquées à des extraits complexes de protéines issus de Vitis vinifera.Flavonoids are natural substances known for their anti-inflammatory, anti-cancerous and anti-virals properties in humans. In plants, they are one of the molecules responsible for fighting pathogens. The flavonoid biosynthesis pathway as been greatly studied in plants, especially in that of the grapevine: Vitis vinifera. However, detailed studies of the exact function of the enzymes involved in the last steps of the biosynthesis of anthocyanins and proanthocyanidins remains largely lacking.The study that we propose is to synthesize molecular probes designed to specifically interact with enzymes involved in the last stages of flavonoids biosynthesis. Our probes, based on the emerging chemical proteomic technology, activity- and affinity based protein profiling (ABPP), were validated with a model enzyme: leucoanthocyanidin dioxygenase (LDOX). After which, they were used with complex protein mixtures from Vitis vinifera

Molecular probes development for Flavonoid biosynthesis studying

Les flavonoïdes sont des substances naturelles connues pour leurs propriétés anti-inflammatoires, anti-cancéreuses ou anti-virales chez l'homme. Chez les végétaux, ils participent notamment à leur protection vis-à-vis d'organismes pathogènes. La voie de biosynthèse des flavonoïdes est l'une des plus étudiées chez les plantes et notamment chez la vigne : Vitis vinifera. Cependant, la ou les enzymes impliquées dans les dernières étapes de biosynthèse conduisant aux anthocyanes et aux proanthocyanidines restent, à ce jour, peu ou pas connues. L’étude que nous proposons a pour but de concevoir des sondes moléculaires d’affinité susceptibles d’interagir avec une ou plusieurs enzymes impliquées dans ces dernières étapes de biosynthèse. Ces sondes, basées sur la technologie émergeante de protéomique chimique : « Activity- and affininity Based Protein Profiling » (ABPP), ont été validées à l’aide d’une enzyme modèle : la leucoanthocyanidine dioxygénase (LDOX). Elles ont ensuite été appliquées à des extraits complexes de protéines issus de Vitis vinifera.Flavonoids are natural substances known for their anti-inflammatory, anti-cancerous and anti-virals properties in humans. In plants, they are one of the molecules responsible for fighting pathogens. The flavonoid biosynthesis pathway as been greatly studied in plants, especially in that of the grapevine: Vitis vinifera. However, detailed studies of the exact function of the enzymes involved in the last steps of the biosynthesis of anthocyanins and proanthocyanidins remains largely lacking.The study that we propose is to synthesize molecular probes designed to specifically interact with enzymes involved in the last stages of flavonoids biosynthesis. Our probes, based on the emerging chemical proteomic technology, activity- and affinity based protein profiling (ABPP), were validated with a model enzyme: leucoanthocyanidin dioxygenase (LDOX). After which, they were used with complex protein mixtures from Vitis vinifera

Nanoparticles highly loaded with gentamicin sulfate by a combination of polyhydroxylated macromonomers and ROMP for the synthesis of bioactive biomaterials

Antibiotic functionalized polymeric nanoparticles (NPs) are obtained by the copolymerization of macromonomers, which is a powerful way to synthesize bioactive biomaterial surfaces able to fight a bacterial strain in the case of infection. The active molecule loading can be modulated/increased by the use of highly charged macromonomers (typically polyhydroxylated macromonomers). This paper presents the synthesis of α-norbornenyl hydroxylated macromonomers (polyglycidol and poly(ethylene oxide)-block-polyglycidol) functionalized with an antibiotic: gentamicin sulfate. Then, these macromonomers are copolymerized with norbornene (Nb) by ring-opening metathesis polymerization in a dispersion to form core–shell NPs which have application as antibiotic platforms for the synthesis of bioactive biomaterial surfaces

Vancomycin Functionalized Nanoparticles for Bactericidal Biomaterial Surfaces

In this paper, we describe a simple and powerful way to synthesize antibacterial biomaterials with applications as implants in orthopedic surgery. Such implants are obtained by covalently grafting onto the Ti90A16 V4 alloy surface with vancomycin-functionalized nanoparticles. Nanoparticles were produced by ring-opening metathesis polymerization of alpha-norbornenyl-omega-vancomycin poly(ethylene oxide) macromonomers. Vancomycin is an interesting candidate because of its use in the field of implant associated infection as it is a glycopeptide which acts on bacterial walls. As a consequence, vancomycin does not need to be released for it to be active. In the first part of this paper, the synthesis and the complete characterization of these materials are described. In a second part, the in vitro antibacterial behavior is analyzed and discussed

Suggestions for the care of patients with liver disease during the Coronavirus 2019 pandemic

International audienc

Twelve month clinical and angiographic outcome after stenting of unprotected left main coronary artery stenosis with paclitaxel-eluting stents--results of the multicentre FRIEND registry.

International audienceAIMS: To evaluate the angiographic and clinical outcome of patients undergoing paclitaxel-eluting stent (PES) implantation for unprotected left main coronary artery (ULMCA) stenosis in a multicentre, prospective registry. The overall event rate for PCI of ULMCA disease remains higher than in on-label use making additional outcome data and risk-stratification tools for the ULMCA population desirable. METHODS AND RESULTS: A prospective registry included all patients with a significant (> 50%) stenosis in ULMCA disease. In 151 of these patients the target lesion involved the distal bifurcation in 100 patients (66%), which was treated by predominantly using a "provisional T stenting" strategy. In distal ULMCA disease group, 72% had only one stent implantation while 28% had multiple (either 2 or 3) stents implanted. At a median follow-up of 472 +/- 75 days, cardiac death occurred in 3 patients (2%) and major adverse cardiac and cerebrovascular events (MACCE) in 16 patients (10.6%). CONCLUSIONS: In the drug-eluting stent era, paclitaxel eluting stent implantation of ULMCA stenosis provided excellent immediate and mid-term results in this selected population, suggesting that it may be considered as a safe and effective alternative to CABG for selected patients with ULMCA who are treated in institutions performing large numbers of PCI procedures